Rhian Gabe, Philip A J Crosbie, Daniel Vulkan, Hannah Bailey, David R Baldwin, Claire Bradley, Richard Booton, Michael J Darby, Claire Eckert, Neil Hancock, Sebastian Hinde, Sam M Janes, Martyn P T Kennedy, Catriona Marshall, Henrik Moller, Rachael L Murray, Richard D Neal, Samantha L Quaife, Suzanne Rogerson, Bethany Shinkins, Irene Simmonds, Sara Upperton, Matthew E J Callister
{"title":"在约克郡肺筛查试验中肺癌筛查资格标准和肺癌检测的前瞻性评价。","authors":"Rhian Gabe, Philip A J Crosbie, Daniel Vulkan, Hannah Bailey, David R Baldwin, Claire Bradley, Richard Booton, Michael J Darby, Claire Eckert, Neil Hancock, Sebastian Hinde, Sam M Janes, Martyn P T Kennedy, Catriona Marshall, Henrik Moller, Rachael L Murray, Richard D Neal, Samantha L Quaife, Suzanne Rogerson, Bethany Shinkins, Irene Simmonds, Sara Upperton, Matthew E J Callister","doi":"10.1016/j.jtho.2024.12.016","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Low-dose computed tomography screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung Screening Trial was designed to evaluate lung cancer screening (LCS) implementation, and a primary objective was prospective evaluation of three predefined eligibility criteria.</p><p><strong>Methods: </strong>Individuals who had ever smoked, aged 55 to 80 years, who responded to written invitation, underwent telephone risk assessment and if eligible by at least one criterion (PLCO<sub>M2012</sub> ≥ 1.51%, LLP<sub>v2</sub> ≥ 5%, USPSTF<sub>2013</sub>) were offered biennial low-dose computed tomography screening.</p><p><strong>Results: </strong>Of 44,957 individuals invited, 22,814 responded and underwent eligibility assessment, of whom a total of 7826 were eligible according to any of the three LCS criteria. Comparing PLCO<sub>M2012</sub> ≥ 1.51%, LLP<sub>v2</sub> ≥ 5%, and USPSTF<sub>2013</sub>, the proportions of responders eligible for screening were 28.0%, 20.5%, and 18.9%, respectively (p < 0.0001 for each comparison), and the proportion of all cancers detected 91.1%, 77.0%, and 62.8%, respectively (p ≤ 0.0002 for each comparison). When risk thresholds were selected to result in equivalent numbers of people eligible for screening, cancer detection proportions were higher for PLCO<sub>M2012</sub> (74.5%) and LLP<sub>v2</sub> (71.3%) than USPSTF<sub>2013</sub> (62.8%) (p = 0.0002 and p = 0.032, respectively), but there was no significant difference between the two risk models. Reducing the LLPv2 risk threshold from 5% to 2.5% (as currently used in the English LCS program) and reducing the pack-year requirement for the USPSTF<sub>2021</sub> versus the USPSTF<sub>2013</sub> criteria increased the numbers eligible for screening, but subsequent cancer yield was not measured in this study.</p><p><strong>Conclusion: </strong>The PLCO<sub>M2012</sub> ≥ 1.51% criteria identified more people eligible for screening in Yorkshire Lung Screening Trial and resulted in more screen-detected lung cancers than LLP<sub>v2</sub> ≥ 5% or USPSTF<sub>2013</sub>. When compared in equivalent populations, there was no significant difference between risk models in terms of lung cancer detection and each appeared more efficient at screening population selection than USPSTF<sub>2013</sub>.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prospective Evaluation of Lung Cancer Screening Eligibility Criteria and Lung Cancer Detection in the Yorkshire Lung Screening Trial.\",\"authors\":\"Rhian Gabe, Philip A J Crosbie, Daniel Vulkan, Hannah Bailey, David R Baldwin, Claire Bradley, Richard Booton, Michael J Darby, Claire Eckert, Neil Hancock, Sebastian Hinde, Sam M Janes, Martyn P T Kennedy, Catriona Marshall, Henrik Moller, Rachael L Murray, Richard D Neal, Samantha L Quaife, Suzanne Rogerson, Bethany Shinkins, Irene Simmonds, Sara Upperton, Matthew E J Callister\",\"doi\":\"10.1016/j.jtho.2024.12.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Low-dose computed tomography screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung Screening Trial was designed to evaluate lung cancer screening (LCS) implementation, and a primary objective was prospective evaluation of three predefined eligibility criteria.</p><p><strong>Methods: </strong>Individuals who had ever smoked, aged 55 to 80 years, who responded to written invitation, underwent telephone risk assessment and if eligible by at least one criterion (PLCO<sub>M2012</sub> ≥ 1.51%, LLP<sub>v2</sub> ≥ 5%, USPSTF<sub>2013</sub>) were offered biennial low-dose computed tomography screening.</p><p><strong>Results: </strong>Of 44,957 individuals invited, 22,814 responded and underwent eligibility assessment, of whom a total of 7826 were eligible according to any of the three LCS criteria. Comparing PLCO<sub>M2012</sub> ≥ 1.51%, LLP<sub>v2</sub> ≥ 5%, and USPSTF<sub>2013</sub>, the proportions of responders eligible for screening were 28.0%, 20.5%, and 18.9%, respectively (p < 0.0001 for each comparison), and the proportion of all cancers detected 91.1%, 77.0%, and 62.8%, respectively (p ≤ 0.0002 for each comparison). When risk thresholds were selected to result in equivalent numbers of people eligible for screening, cancer detection proportions were higher for PLCO<sub>M2012</sub> (74.5%) and LLP<sub>v2</sub> (71.3%) than USPSTF<sub>2013</sub> (62.8%) (p = 0.0002 and p = 0.032, respectively), but there was no significant difference between the two risk models. Reducing the LLPv2 risk threshold from 5% to 2.5% (as currently used in the English LCS program) and reducing the pack-year requirement for the USPSTF<sub>2021</sub> versus the USPSTF<sub>2013</sub> criteria increased the numbers eligible for screening, but subsequent cancer yield was not measured in this study.</p><p><strong>Conclusion: </strong>The PLCO<sub>M2012</sub> ≥ 1.51% criteria identified more people eligible for screening in Yorkshire Lung Screening Trial and resulted in more screen-detected lung cancers than LLP<sub>v2</sub> ≥ 5% or USPSTF<sub>2013</sub>. When compared in equivalent populations, there was no significant difference between risk models in terms of lung cancer detection and each appeared more efficient at screening population selection than USPSTF<sub>2013</sub>.</p>\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2024-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jtho.2024.12.016\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtho.2024.12.016","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prospective Evaluation of Lung Cancer Screening Eligibility Criteria and Lung Cancer Detection in the Yorkshire Lung Screening Trial.
Introduction: Low-dose computed tomography screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung Screening Trial was designed to evaluate lung cancer screening (LCS) implementation, and a primary objective was prospective evaluation of three predefined eligibility criteria.
Methods: Individuals who had ever smoked, aged 55 to 80 years, who responded to written invitation, underwent telephone risk assessment and if eligible by at least one criterion (PLCOM2012 ≥ 1.51%, LLPv2 ≥ 5%, USPSTF2013) were offered biennial low-dose computed tomography screening.
Results: Of 44,957 individuals invited, 22,814 responded and underwent eligibility assessment, of whom a total of 7826 were eligible according to any of the three LCS criteria. Comparing PLCOM2012 ≥ 1.51%, LLPv2 ≥ 5%, and USPSTF2013, the proportions of responders eligible for screening were 28.0%, 20.5%, and 18.9%, respectively (p < 0.0001 for each comparison), and the proportion of all cancers detected 91.1%, 77.0%, and 62.8%, respectively (p ≤ 0.0002 for each comparison). When risk thresholds were selected to result in equivalent numbers of people eligible for screening, cancer detection proportions were higher for PLCOM2012 (74.5%) and LLPv2 (71.3%) than USPSTF2013 (62.8%) (p = 0.0002 and p = 0.032, respectively), but there was no significant difference between the two risk models. Reducing the LLPv2 risk threshold from 5% to 2.5% (as currently used in the English LCS program) and reducing the pack-year requirement for the USPSTF2021 versus the USPSTF2013 criteria increased the numbers eligible for screening, but subsequent cancer yield was not measured in this study.
Conclusion: The PLCOM2012 ≥ 1.51% criteria identified more people eligible for screening in Yorkshire Lung Screening Trial and resulted in more screen-detected lung cancers than LLPv2 ≥ 5% or USPSTF2013. When compared in equivalent populations, there was no significant difference between risk models in terms of lung cancer detection and each appeared more efficient at screening population selection than USPSTF2013.
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.